Healthcare - Biotechnology - NASDAQ - US
$ 3.47
-12.2 %
$ 247 M
Market Cap
-1.31
P/E
CASH FLOW STATEMENT
-208 M
OPERATING CASH FLOW
-44.5 M
INVESTING CASH FLOW
237 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Zentalis Pharmaceuticals, Inc.
| Net Income | -292 M |
| Depreciation & Amortization | 1.39 M |
| Capital Expenditures | -583 K |
| Stock-Based Compensation | 54.8 M |
| Change in Working Capital | 5.86 M |
| Others | 18.1 M |
| Free Cash Flow | -208 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (292.2) | (237.1) | (166.1) | (118.5) | (46.4) | (23.4) |
| Depreciation & Amortization | 1.4 | 1.4 | 0.5 | 0.2 | 0.1 | 51 K |
| Deferred Income Tax | (0.9) | (0.8) | (2.5) | 17 K | 7.8 | 2.4 |
| Stock Based Compensation | 54.8 | 46.8 | 35.7 | 23.1 | 0.6 | 0.3 |
| Other Operating Activities | 23.1 | 12.6 | (38.4) | 0.6 | (7.8) | (2.4) |
| Change in Working Capital | 5.9 | 13.3 | 16.6 | 7.8 | 6.5 | (1.2) |
| Cash From Operations | (207.8) | (163.8) | (154.1) | (86.8) | (39.1) | (24.3) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.6) | (2.5) | (6.1) | (0.8) | (0.4) | (0.2) |
| Other Items | (43.9) | (111.6) | (12.0) | (284.1) | 0 | 0 |
| Cash From Investing Activities | (44.5) | (114.2) | (18.1) | (284.8) | (0.4) | (0.2) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (1.1) | 32.7 | 81.8 | 9.5 |
| Cash From Financing Activities | 237.3 | 261.0 | 178.5 | 360.4 | 81.8 | 9.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (15.0) | (16.9) | 6.3 | (11.2) | 42.3 | (15.0) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (208.4) | (166.3) | (160.2) | (87.6) | (39.5) | (24.5) |